Literature DB >> 31650406

The Impact of Dietician Support and Behavioural Therapy in Addition to Concomitant Treatment with Intragastric Balloon in Obese Patients.

Salvatore Francesco Vadalà di Prampero1,2, Sonia Solito3, Giacomo Faleschini4, Nikola Panic5,6, Luigi Castriotta7, Alessandro Picci3, Eleonora Pinese3, Rossana Piva8, Milutin Bulajic9,3, Marco Marino3, Piera Rossitti3, Maurizio Zilli3.   

Abstract

INTRODUCTION AND AIMS: Patients treated with intragastric balloon (IGB) may benefit from treatment and follow-up by a multidisciplinary team, where the dietician is considered the only essential professional besides the endoscopist. The aim of this study is to evaluate the impact of dietician support and behavioral therapy in terms of weight loss in patients concomitantly treated with IGB while the device is in situ.
METHODS: Patients with IGB in situ, in period 2005-2018, were invited to undergo a dietician check-up (DC) every 1.5 months, accompanied by cognitive behavioral therapy. Considering their attendance at the dietician check-ups (DCs), patients were categorized as non-compliant (0 DC), partially compliant (1-2 DCs), and highly compliant (≥ 3 DCs). A comparison was made among the three groups regarding % of total body weight loss (%TBWL) and ΔBMI at 180 ± 15 days when the IGB was in situ.
RESULTS: One hundred eighty-three obese patients treated with fluid-filled IGB were included. Body weight data at 180 ± 15 days during the IGB in situ, as well as attendance at the DCs, were available for 170 out of 183 patients. There was no difference among compliant, partially compliant, and non-compliant patients to DCs regarding %TBWL at 180 ± 15 days (p = 0.17). However, non-compliant patients had a higher ΔBMI at 180 ± 15 days in comparison to those compliant or partially compliant to DCs (p = 0.03).
CONCLUSION: Despite its undisputed educational role, attendance at DCs does not seem to correlate with an additional weight loss while the IGB is in situ.

Entities:  

Keywords:  Dietician support; Intragastric Balloon; Weight loss

Mesh:

Year:  2020        PMID: 31650406     DOI: 10.1007/s11695-019-04228-1

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  25 in total

Review 1.  Balancing risk and reward: a critical review of the intragastric balloon for weight loss.

Authors:  Shantanu Gaur; Samuel Levy; Lisbeth Mathus-Vliegen; Ram Chuttani
Journal:  Gastrointest Endosc       Date:  2015-04-14       Impact factor: 9.427

Review 2.  Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases.

Authors:  Manoel Galvao Neto; Lyz Bezerra Silva; Eduardo Grecco; Luiz Gustavo de Quadros; André Teixeira; Thiago Souza; Jimi Scarparo; Artur A Parada; Ricardo Dib; Rena Moon; Josemberg Campos
Journal:  Surg Obes Relat Dis       Date:  2017-09-28       Impact factor: 4.734

3.  Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study.

Authors:  Maria Luisa De Castro; María José Morales; Víctor Del Campo; Juan R Pineda; Eduardo Pena; José M Sierra; María José Arbones; Ignacio R Prada
Journal:  Obes Surg       Date:  2010-12       Impact factor: 4.129

Review 4.  The Epidemiology of Obesity: A Big Picture.

Authors:  Adela Hruby; Frank B Hu
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

Review 5.  Dietary approaches to the treatment of obesity.

Authors:  Angela Makris; Gary D Foster
Journal:  Psychiatr Clin North Am       Date:  2011-12

6.  Intragastric balloon as an artificial bezoar for treatment of obesity.

Authors:  O G Nieben; H Harboe
Journal:  Lancet       Date:  1982-01-23       Impact factor: 79.321

Review 7.  Review of endoscopic devices for weight reduction: old and new balloons and implantable prostheses.

Authors:  N Tsesmeli; D Coumaros
Journal:  Endoscopy       Date:  2009-11-06       Impact factor: 10.093

Review 8.  ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.

Authors:  Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee
Journal:  Gastrointest Endosc       Date:  2015-07-29       Impact factor: 9.427

9.  Treatment of morbid obesity with intragastric balloon in association with diet.

Authors:  S B Doldi; G Micheletto; M N Perrini; M C Librenti; S Rella
Journal:  Obes Surg       Date:  2002-08       Impact factor: 4.129

10.  Advances in endoscopic balloon therapy for weight loss and its limitations.

Authors:  Dinesh Vyas; Kaivalya Deshpande; Yagnik Pandya
Journal:  World J Gastroenterol       Date:  2017-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.